ABSTRACT
The efficacy and tolerability of the combined scheme of administering high dose medroxyprogesterone acetate in advanced breast cancer is evaluated.
Subject(s)
Administration, Oral , Aged , Antineoplastic Agents/administration & dosage , Breast Neoplasms/drug therapy , Female , Humans , Injections, Intramuscular , Medroxyprogesterone/administration & dosage , Medroxyprogesterone Acetate , Middle AgedABSTRACT
Twenty-two patients with advanced or recurrent cancer of the cervix treated with cis-platinum, adriamycin and cyclophosphamide were evaluated. Nine of 22 (41% achieved objective response (2 CR + 7PR), 9/22 (41%) stable disease, 4/22 (18%) progressive disease. The mean duration of response was 24.6 weeks, with a range of 18-28 weeks. Patients with poorly differentiated histologic grade and without previous treatment had better response rates. Responders had longer survival (mean 63.5 + weeks) than nonresponders (mean 30.5 weeks). Commonly encountered toxicities were alopecia, nausea and vomiting, and leucopenia, which were all tolerable.